Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05279300 · ClinicalTrials.gov registry record · Phase 1

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

A Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma, sponsored by CStone Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
480
Enrollment target
20
Study locations

NCT05279300 is a Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma that is actively recruiting participants, run by CStone Pharmaceuticals. The registered enrollment target is 480 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (153% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05279300, a Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma, is actively recruiting participants, sponsored by CStone Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.

Conditions Studied

Advanced Solid Tumor Advanced Lymphoma

Interventions

  • DRUG Oxaliplatin
  • DRUG Lenalidomide
  • DRUG Gemcitabine
  • BIOLOGICAL Rituximab
  • DRUG CS5001

Study Locations (20)

South Australia

  • Ashford Cancer Centre Research - Adelaide
  • Central Adelaide Local Health Network Incorporated - Adelaide
  • Royal Adelaide Hospital (RAH) - Adelaide

Beijing Municipality

  • Beijing Cancer Hospital - Beijing
  • Beijing Cancer Hospital - Beijing
  • Yanda Lu Dao Pei Hospital - Beijing

New York

  • North Shore Hematology Oncology Associates - East Setauket
  • Columbia U. - Herbert Irving Comprehensive Cancer Center - New York

Victoria

  • Epworth Freemasons Medical Centre - East Melbourne
  • Epworth Foundation trading as Epworth HealthCare - Melbourne

Anhui

  • Anhui Provincial Cancer Hospital - Hefei
  • Anhui Provincial Hospital, - Hefei

Guangdong

  • Guangdong Province Hospital - Guangzhou
  • Sun YatSen University Cancer Center - Guangzhou

Texas

  • BUMC - Mary Crowley Cancer Research Centers (MCCRC) - Dallas

New South Wales

  • Scientia Clinical Research Limited - Randwick

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2022-03-28
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

CStone Pharmaceuticals

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05279300

The ClinicalTrials.gov registry entry for NCT05279300 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (153% higher). The listed sponsor is CStone Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Oxaliplatin is the first listed.

NCT05279300 reports 20 study locations spanning 12 distinct geographic areas - top geographies include South Australia, Beijing Municipality, New York.

Frequently Asked Questions

What is clinical trial NCT05279300 about?

NCT05279300 is a clinical study titled "A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas". This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.

What is the current status of trial NCT05279300?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 480 participants. The study started on 2022-03-28. Estimated completion is 2027-12-31.

What conditions does trial NCT05279300 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Lymphoma.

What interventions are being tested in trial NCT05279300?

The interventions under investigation include: Oxaliplatin (DRUG), Lenalidomide (DRUG), Gemcitabine (DRUG), Rituximab (BIOLOGICAL), CS5001 (DRUG).

Who is sponsoring clinical trial NCT05279300?

This trial is sponsored by CStone Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05279300 being conducted?

This trial has 20 study locations across New York, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Advanced Lymphoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.